Back to Search
WILLIAM NOVOTNY, MD
MD
Pediatric Critical Care Medicine Physician
NPI: 1922092428IndividualAccepts Medicare
Specialties, Licenses & Credentials
Pediatric Critical Care Medicine PhysicianPrimary
Pediatrics — Pediatric Critical Care Medicine
Code: 2080P0203X
9300777(NC)
CMS Specialties
PrimaryPEDIATRIC MEDICINE
Education
UNIVERSITY OF TOLEDO COLLEGE OF MEDICINE
Class of 1981
Research & Publications (20)
Pulmonary hemorrhage in an infant following 2 weeks of fungal exposure.
PMID 10710026·Arch Pediatr Adolesc Med·2000
5-case
The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
PMID 19144677·Oncologist·2009
3-trial
Clinical pharmacokinetics of bevacizumab in patients with solid tumors.
PMID 18205003·Cancer Chemother Pharmacol·2008
8-other
An 18-yr prospective study of pediatric diabetic ketoacidosis: an approach to minimizing the risk of brain herniation during treatment.
PMID 17550424·Pediatr Diabetes·2007
4-observational
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.
PMID 16365183·J Clin Oncol·2006
2-rct
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
PMID 16118771·J Surg Oncol·2005
8-other
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
PMID 15998951·J Natl Cancer Inst·2005
8-other
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
PMID 15961063·Biochem Biophys Res Commun·2005
6-review
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
PMID 15908660·J Clin Oncol·2005
3-trial
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
PMID 15738537·J Clin Oncol·2005
3-trial
Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma.
PMID 15221991·Cancer·2004
3-trial
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
PMID 15175435·N Engl J Med·2004
3-trial
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.
PMID 15169807·J Clin Oncol·2004
3-trial
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
PMID 15136787·Nat Rev Drug Discov·2004
6-review
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.
PMID 14613032·Semin Oncol·2003
3-trial
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
PMID 12506171·J Clin Oncol·2003
3-trial
Continuous venovenous hemodiafiltration in hypernatremic hyperglycemic nonketotic coma.
PMID 12432445·Pediatr Nephrol·2002
5-case
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
PMID 11821453·J Clin Oncol·2002
3-trial
First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report.
PMID 11342197·Eur J Cancer·2001
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2150 HERBERT CT, ECU PHYSICIANS PEDIATRIC NEPHROLOGY
GREENVILLE, NC 27834 - Phone
- (252) 744-5437
Quick Facts
- NPI
- 1922092428
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 45
- Publications
- 20
Are you this provider?
Claim Your Profile